Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Robin Solymanijam

Pulmonary Disease Beverly Hills, CA Medical Doctor

NPI 1811180144 CMS profile 309481

8536 Wilshire Blvd Ste 201, Beverly Hills, CA 90211

Open in the dashboard

General payments

$4,064

191 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Robin Solymanijam of Beverly Hills, CA is reported in the CMS Open Payments database as having received $4,064 across 191 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 63rd percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $340 14
2024 General $687 31
2023 General $1,089 49
2022 General $33 1
2021 General $160 7
2020 General $851 40
2019 General $904 49

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Robin Solymanijam
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Robin Solymanijam were reported at $340. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Robin Solymanijam Pulmonary Disease median Middle half National median
2019 $904 $377 $109–$1,340 $163
2020 $851 $230 $56–$907 $114
2021 $160 $269 $68–$1,072 $132
2022 $33 $390 $100–$1,457 $149
2023 $1,089 $419 $114–$1,659 $160
2024 $687 $476 $123–$1,818 $164
2025 $340 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $973 50 payments
  2. AstraZeneca Pharmaceuticals LP $795 39 payments
  3. Amgen Inc. $398 19 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $365 17 payments
  5. Genzyme Corporation $333 15 payments
  6. Philips Electronics North America Corporation $206 10 payments
  7. Bayer HealthCare Pharmaceuticals Inc. $133 6 payments
  8. Genentech USA, Inc. $121 6 payments
  9. Baxter Healthcare $118 4 payments
  10. United Therapeutics Corporation $108 5 payments
  11. Other $512 20 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,955 188 payments
  2. Education $110 3 payments
Products named General payments · program years 2019–2025
  1. TRELEGY ELLIPTA $420 22 payments
  2. TEZSPIRE $398 19 payments
  3. DUPIXENT $365 14 payments
  4. OFEV $350 19 payments
  5. SYMBICORT $292 14 payments
  6. NUCALA Respiratory $226 7 payments
  7. NUCALA Immunology $192 11 payments
  8. FASENRA Respiratory $176 8 payments
  9. AIRSUPRA $173 7 payments
  10. FASENRA Respiratory $161 8 payments
  11. Other $1,958 91 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 58 drugs

Part D claims

1,868

Median for Pulmonary Disease: 936

Drug cost

$903,448

Median for Pulmonary Disease: $487,987

Branded share of claims

48.3%

Median for Pulmonary Disease: 69.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ofev Nintedanib Esylate Brand 18 $306,009
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 238 $250,885
Tezspire Tezepelumab-Ekko Brand 28 $137,810
Spiriva Respimat Tiotropium Bromide Brand 38 $45,078
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 53 $41,508
Breo Ellipta Fluticasone/Vilanterol Brand 52 $30,757
Eliquis Apixaban Brand 20 $13,695
Ozempic Semaglutide Brand 11 $9,867
Xarelto Rivaroxaban Brand 11 $8,746
Arnuity Ellipta Fluticasone Furoate Brand 27 $8,046

The 10 drugs with the highest cost, of 58 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,233 Part D prescribers listed as Pulmonary Disease; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 36 billing codes

Paid by Medicare

$215,619

Of which drugs: $955

Medicare patients

402

Average age 75

Services billed

3,171

228 women, 174 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 63%
Ischemic heart disease 58%
COPD 54%
Diabetes 46%
Heart failure 43%
Chronic kidney disease 37%
Depression 36%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone sodium succinate, 5 mg J2919 Office 23 725 $166
Injection, methylprednisolone sodium succinate, up to 125 mg J2930 Office 12 12 $41
Injection, ceftriaxone sodium, per 250 mg J0696 Office 19 100 $32
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg J7613 Office 15 48 $2

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 11 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TEZSPIRE
  • Amgen Inc. $216
$216 28 —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $99
$99 — —
DUPIXENT
  • GENZYME CORPORATION $83
$83 — —
FASENRA
  • AstraZeneca Pharmaceuticals LP $72
$72 — —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $50
$50 238 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 11 in the dashboard with a free account

Records

191 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record